Update on the safety of itraconazole pulse therapy in onychomycosis and dermatomycoses

As the use of newer antifungal agents becomes more widespread, safety issue s surrounding their use have become more important. To date, the safety pro file of itraconazole has been well defined by its worldwide use in 50 milli on patients: over the past 13 years. Data from clinical practice and clinic al trials indicate that the 1-week pulse regimen of itraconazole is well to lerated and associated with a favourable safety profile. Adverse events are generally mild and transient. Furthermore, a dose increase to 400 mg in th e pulse regimen has had no adverse impact on safety.